ASPIrin in Reducing Events in Dialysis ( ASPIRED )

People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.

NCT Number	NCT04381143
Lead Sponsor	Guangdong Provincial People's Hospital Collaborators: The George Institute
Conditions	CKD (Chronic Kidney Disease) Stage 5D
Enrollment	9,000 participants
Start Date	2020-07-30
Primary Completion	2026-09 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-11-18